Apostle Inc is pleased to announce that the company is going to present at the 5th Liquid Biopsy Summit, to take place in Seattle, WA on June 15-17, 2020. David Ge, CEO of Apostle, will discuss Apostle MiniEnrich, a novel method for enrichment of short DNA fragments for NIPT and oncology applications.
The fragment sizes of circulating free DNA show subtle variability from different origins, for example, fetal vs. maternal, cancer vs. normal. The current liquid biopsy technologies offer little resolution in differentiating and enriching for this small but important difference, resulting in sample rejections, test inaccuracies, and limited clinical utility of liquid biopsies. In the Summit, Apostle will present a novel method, termed Apostle MiniEnrich, to address this challenge and efficiently capture this subtle variability, with data showing significant enrichment of target cfDNA fragments (Average Fetal Fraction/FF before enrichment = 12.96%; Average FF after enrichment = 19.92%; Average Delta FF = 6.97%, P = 0.001). This method may have the potential to rescue rejected or non-reportable clinical samples and improve test accuracy, and may enable a much broader utility of liquid biopsies.
“I’m thrilled to join the prestigious speakers and organizations in the Summit.”, said David. “I would like to thank the Liquid Biopsy Summit and its Scientific Review Committee for selecting Apostle’s work.”
For more details of the Summit, visit: https://www.liquidbiopsysummit.com/programs.
Apostle Inc is selected to present at the Precision Medicine World Conference (PWMC) 2020, held in Santa Clara Convention Center, California on January 21-24, 2020.
David Ge, CEO of Apostle Inc, attended the conference and presented in the conference’s Liquid Biopsy Showcase track. The PMWC 2020 Liquid Biopsy Showcase provides a 15-minute time slot for selected liquid biopsy companies to present their latest technologies to an audience of leading investors, potential clients, and partners. The track features companies that advance the development of screening tests for oncology, immunotherapy, and other areas, based on detection and identification of circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), circulating RNA, circulating microRNAs, or extracellular vesicle (exosomes).
“cfDNA isolation, purification, and selection is a critical yet unaddressed challenge in liquid biopsy.” David said, “The acclaimed Apostle MiniMax high efficiency cfDNA isolation technology, as well as the new incoming Apostle MiniEnrich short-fragment cfDNA selection technology, answers for this challenge and ensures a successful liquid biopsy test.”
For more information, visit: https://www.pmwcintl.com/session/liquid-biopsy-showcase_2020sv/
Two independent studies were presented at the American Society of Human Genetics (ASHG) 2019 Annual Meeting, comparing paired FFPE tumor
tissue and cfDNA samples, and paried whole blood and cfDNA samples. Majority of variants that are found when sequencing FFPE DNA could
be captured by sequencing cfDNA. Variants found only in cfDNA compared with whole blood could be used as an initial screen for ctDNA analysis.
cfDNA samples were prepared using the Apostle MiniMaxTM technology.
Apostle MiniMax is featured in Science, New Products section, 2019;364(6441):696.
Apostle Inc is pleased to receive the Certificates of Conformance to certify that Quality Management System of Apostle Inc. 1455 Adams Dr. Menlo Park, CA 94025, USA has been assessed by ABS Quality Evaluations, Inc. and found to be in conformance with the requirements set forth by: ISO13485:2016, and ISO9001:2015. The Quality Management System is applicable to DEVELOPMENT, MANUFACTURING, LICENSING AND SALES OF CONSUMABLES AND CHEMICALS FOR NUCLEIC ACID RESEARCH.
An independent study was presented at the American Association for Cancer Research (AACR) 2019 Annual Meeting, comparing paired FFPE tumor
tissue and cfDNA samples. Both FFPE and cfDNA detect at least two thirds of the observed indels and at least 90% of the observed SNVs.
cfDNA samples were prepared using the Apostle MiniMaxTM technology.
Apostle Inc is pleased to have been awarded ISO 13485 certification for our
Nucleic Acid Extraction or
Purification Reagents of Research and Development, Production, and Sales in our manufacturing facility
located in Shenzhen, China. This certificate demonstrates our commitment to providing a high-quality and consistent
service to our clients and our ongoing investment in technology, development, processes and procedures.
ISO 13485, Medical devices – Quality management systems – Requirements for regulatory purposes, is an internationally agreed standard that sets out the requirements for a quality management system specific to the medical devices industry. It has recently been revised, with the new version published in March 2016.
Beckman Coulter Life Sciences announces an exclusive partnership with Apostle, a liquid biopsy company, on Feb 28, 2019.
For more information about this partnership:
Apostle MiniMaxTM technology is independently validated and the findings are presented at the
Advances in Genome Biology and Technology (AGBT) 2019 meeting in Marco Island, FL. Apostle MiniMaxTM is efficient, clean,
scalable, automatable, versatile, and novel.
Apostle Inc is pleased to receive the trademark registration certificates for APOSTLE and APOSTLE MINIMAX from the United States Patent and Trademark Office on Nov 21, 2018. The registration dates for both trademarks are July 24, 2018.
Apostle Inc is pleased to have been awarded ISO 9001 certification for our
R&D, Manufacturing and Sales of Nucleic Acid Extraction and
Purification Kits in our manufacturing facility located in Shenzhen, China.
This certificate demonstrates our commitment to providing a high-quality and consistent service to
our clients and our ongoing investment in technology, development, processes and procedures.
ISO 9001 is the international standard that specifies requirements for a quality management system (QMS). Organizations use the standard to demonstrate the ability to consistently provide products and services that meet customer and regulatory requirements. It is the most popular standard in the ISO 9000 series and the only standard in the series to which organizations can certify.
StartX is a renowned educational non-profit that accelerates the development of Stanford's top entrepreneurs
through experiential education and collective intelligence.
The Stanford-StartX Fund (SSF), co-founded by StartX, Stanford University, and Stanford Health Care is
available only to StartX companies with a Stanford-affiliated founder.
StartX alumni and trusted expert judges review and determine which teams are accepted. The acceptance rate has been between 8%-10%. Apostle is selected into the StartX Accelerator Program (Summer 2018 session), following one initial review, four interviews and due diligence.
Apostle Inc is selected into the Top 20 Life Science Startups to Watch in 2018 by BioSpace on January 2,
The NextGen Bio Class of 2018 is "a list of 20 up-and-coming life science companies in North America
that started up no earlier than 2015, a stellar group of companies that are already making an enormous
impact on the industry now and will into the future."
Companies in the field of genomic sciences selected in the past three years include:
Apostle Inc is pleased to submit its PCT patent application to the U.S. patent and trademark office on Nov 3, 2017.
Apostle won the Second Place in the Final of North America Region, CACSC，(Create@AlibabaCloud Startup Contest). Over 300 startups from North America have competed in CACSC, and 13 entered the final.
Apostle Inc is selected into the Amazon Web Service (AWS) Activate Program.The AWS Activate Program is designed for startups in select accelerators, incubators, Seed/VC Funds, and other startup-enabling organizations. Some of the world’s hottest startups, including Airbnb, Slack, and Robinhood, have leveraged the power of AWS to quickly scale.
Apostle Inc is pleased to submit its first PCT patent application to the U.S. patent and trademark office on July 25, 2017.
Apostle Inc’s co-Founder and SVP of Medicine, Wenqi Zeng, MD PhD is a board-certified clinical molecular geneticist and lab director holding certificates and licenses from American Board of Medical Genetics and Genomics (ABMGG), State of California, State of New York, and diploma from American College of Medical Genetics (ACMG), and Harvard Medical School Genetics Training Program.